{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:56:51Z","timestamp":1776067011901,"version":"3.50.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-025-02317-5","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:19:57Z","timestamp":1767683997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cholesteryl Ester Transfer Protein Inhibitors: State of the Science"],"prefix":"10.1007","volume":"28","author":[{"given":"Mojgan","family":"Nejabat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Hadizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2317_CR1","doi-asserted-by":"publisher","DOI":"10.4137\/CMC.S32667","volume":"10","author":"CE Kosmas","year":"2016","unstructured":"Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. CETP inhibition: past failures and future hopes. Clin Med Insights-Cardiol. 2016;10:CMC.","journal-title":"Clin Med Insights-Cardiol"},{"issue":"2","key":"2317_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/1074248416662349","volume":"22","author":"JH McLain","year":"2017","unstructured":"McLain JH, Alsterda AJ, Arora RR. Cholesteryl ester transfer protein inhibitors: trials and tribulations. J Cardiovasc Pharmacol Ther. 2017;22(2):99\u2013104.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"2317_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008552","volume":"15","author":"N Wang","year":"2022","unstructured":"Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"17","key":"2317_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/heartjnl-2020-318760","volume":"107","author":"C Packard","year":"2021","unstructured":"Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart. 2021;107(17):1369\u201375.","journal-title":"Heart"},{"issue":"1","key":"2317_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.159058","volume":"1867","author":"M Darabi","year":"2022","unstructured":"Darabi M, Kontush A. High-density lipoproteins (HDL): novel function and therapeutic applications. Biochimica et Biophysica Acta (BBA). 2022;1867(1):159058.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"10","key":"2317_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference BA, Kastelein JJ, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318(10):947\u201356.","journal-title":"JAMA"},{"key":"2317_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-016-0724-y","volume":"18","author":"B Di Bartolo","year":"2016","unstructured":"Di Bartolo B, Takata K, Duong M, Nicholls SJ. CETP inhibition in CVD prevention: an actual appraisal. Curr Cardiol Rep. 2016;18:1\u20136.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"2317_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122(1):106\u201312.","journal-title":"Circ Res"},{"issue":"14","key":"2317_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2317_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169417","volume":"23","author":"AJ Nelson","year":"2022","unstructured":"Nelson AJ, Sniderman AD, Ditmarsch M, Dicklin MR, Nicholls SJ, Davidson MH, et al. Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering Apolipoprotein B levels. Int J Mol Sci. 2022;23(16):9417.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2317_CR11","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1016\/j.clinthera.2015.07.021","volume":"37","author":"PJ Barter","year":"2015","unstructured":"Barter PJ, Rye K-A. Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence? Clin Ther. 2015;37(12):2716\u201331.","journal-title":"Clin Ther"},{"issue":"8","key":"2317_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","volume":"35","author":"A Sahebkar","year":"2013","unstructured":"Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082\u201398.","journal-title":"Clin Ther"},{"issue":"6","key":"2317_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","volume":"27","author":"A Sahebkar","year":"2013","unstructured":"Sahebkar A, Watts GF. New therapies targeting ApoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013;27(6):559\u201367.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"2317_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4093\/dmj.2022.0295","volume":"46","author":"K Kim","year":"2022","unstructured":"Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J. 2022;46(5):817\u20138.","journal-title":"Diabetes Metab J"},{"issue":"5","key":"2317_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/CIRCULATIONAHA.115.014026","volume":"132","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Ray KK, Boekholdt SM. Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: suspension of disbelief? Circulation. 2015;132(5):433\u201340.","journal-title":"Circulation"},{"issue":"2","key":"2317_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CRD.0000000000000137","volume":"25","author":"VA Eyvazian","year":"2017","unstructured":"Eyvazian VA, Frishman WH. Evacetrapib: another CETP inhibitor for dyslipidemia with no clinical benefit. Cardiol Rev. 2017;25(2):43\u201352.","journal-title":"Cardiol Rev"},{"issue":"2","key":"2317_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.1118","volume":"104","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ. CETP-inhibition and HDL\u2010cholesterol: a story of CV risk or CV benefit, or both. Clin Pharmacol Ther. 2018;104(2):297\u2013300.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2317_CR18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1194\/jlr.R082735","volume":"59","author":"S Shrestha","year":"2018","unstructured":"Shrestha S, Wu BJ, Guiney L, Barter PJ, Rye K-AJJ. Cholesteryl ester transfer protein and its inhibitors. J Lipid Res. 2018;59(5):772\u201383.","journal-title":"J Lipid Res"},{"issue":"18","key":"2317_CR19","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1007\/s00018-010-0418-3","volume":"67","author":"O Weber","year":"2010","unstructured":"Weber O, Bischoff H, Schmeck C, B\u00f6ttcher. M-FJC, sciences ml. Cholesteryl ester transfer protein and its Inhibition. Cell Mol Life Sci. 2010;67(18):3139\u201349.","journal-title":"Cell Mol Life Sci"},{"issue":"18","key":"2317_CR20","doi-asserted-by":"publisher","first-page":"13215","DOI":"10.1021\/acs.jmedchem.1c00959","volume":"64","author":"P Vachal","year":"2021","unstructured":"Vachal P, Duffy JL, Campeau L-C, Amin RP, Mitra K, Murphy BA, et al. Invention of MK-8262, a cholesteryl ester transfer protein (CETP) inhibitor backup to anacetrapib with best-in-class properties. J Med Chem. 2021;64(18):13215\u201358.","journal-title":"J Med Chem"},{"issue":"7","key":"2317_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9070782","volume":"9","author":"A Kumari","year":"2021","unstructured":"Kumari A, Kristensen KK, Ploug M, Winther A-ML. The importance of lipoprotein lipase regulation in atherosclerosis. Biomedicines. 2021;9(7):782.","journal-title":"Biomedicines"},{"issue":"9","key":"2317_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091083","volume":"9","author":"B Franczyk","year":"2021","unstructured":"Franczyk B, Rysz J, \u0141awi\u0144ski J, Rysz-G\u00f3rzy\u0144ska M, Gluba-Brz\u00f3zka A. Is a high HDL-cholesterol level always beneficial? Biomedicines. 2021;9(9):1083.","journal-title":"Biomedicines"},{"issue":"8","key":"2317_CR23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1194\/jlr.RA120000691","volume":"61","author":"RE Morton","year":"2020","unstructured":"Morton RE, Liu Y. The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins [S]. J Lipid Res. 2020;61(8):1168\u201379.","journal-title":"J Lipid Res"},{"key":"2317_CR24","doi-asserted-by":"publisher","unstructured":"Morton RE, Mihna D, Liu Y. The lipid substrate preference of CETP controls the biochemical properties of HDL in fat\/cholesterol-fed hamsters. J Lipid Res. 2021. https:\/\/doi.org\/10.1016\/j.jlr.2021.100027.","DOI":"10.1016\/j.jlr.2021.100027"},{"key":"2317_CR25","doi-asserted-by":"crossref","unstructured":"Ong K-L, Cochran BJ, Manandhar B, Thomas S, Rye K-A. HDL maturation and remodelling. Biochimica et biophysica acta (BBA)-Molecular and cell biology of lipids. 2022;1867(4):159119.","DOI":"10.1016\/j.bbalip.2022.159119"},{"issue":"16","key":"2317_CR26","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44(16):1394\u2013407.","journal-title":"Eur Heart J"},{"issue":"6","key":"2317_CR27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.1476-5381.2012.02081.x","volume":"167","author":"K Mahdy Ali","year":"2012","unstructured":"Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol\u2013current therapies and future opportunities. Br J Pharmacol. 2012;167(6):1177\u201394.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2317_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/01.ATV.0000205595.19612.c9","volume":"26","author":"AHEM Klerkx","year":"2006","unstructured":"Klerkx AHEM, Harchaoui KE, van der Steeg WA, Boekholdt SM, Stroes ESG, Kastelein JJP, Arteriosclerosis, et al. Thromb Vascular Biology. 2006;26(4):706\u201315.","journal-title":"Thromb Vascular Biology"},{"issue":"15","key":"2317_CR29","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1056\/NEJMoa031766","volume":"350","author":"ME Brousseau","year":"2004","unstructured":"Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"2317_CR30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.jacc.2006.06.066","volume":"48","author":"JM McKenney","year":"2006","unstructured":"McKenney JM, Davidson MH, Shear CL, Revkin JHJJACC. Efficacy and safety of Torcetrapib, a novel cholesteryl ester transfer protein Inhibitor, in individuals with Below-Average High-Density lipoproteincholesterollevelsonabackgroundofatorvastatin. J Am Coll Cardiol. 2006;48(9):1782\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2317_CR31","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322.","journal-title":"N Engl J Med"},{"key":"2317_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s42000-018-0058-9","volume":"17","author":"N Katsiki","year":"2018","unstructured":"Katsiki N, Mikhailidis DPJH. Lipids: a personal view of the past decade. Hormones (Athens). 2018;17:461\u201378.","journal-title":"Hormones (Athens)"},{"issue":"25","key":"2317_CR33","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.2174\/0929867321666140303152132","volume":"21","author":"N Katsiki","year":"2014","unstructured":"Katsiki N, Athyros V, Karagiannis A, Mikhailidis, DJCmc. High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem. 2014;21(25):2917\u201326.","journal-title":"Curr Med Chem"},{"issue":"4","key":"2317_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2459\/JCM.0b013e3283522422","volume":"13","author":"VG Athyros","year":"2012","unstructured":"Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DPJJCM. Should Raising high-density lipoprotein cholesterol be a matter of debate? J Cardiovasc Med. 2012;13(4):254\u20139.","journal-title":"J Cardiovasc Med"},{"issue":"4","key":"2317_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/fca.12.25","volume":"8","author":"D Rhainds","year":"2012","unstructured":"Rhainds D, Arsenault BJ, Brodeur MR, Tardif J-CJFC. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiol. 2012;8(4):513\u201331.","journal-title":"Future Cardiol"},{"issue":"7","key":"2317_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","volume":"33","author":"TF L\u00fcscher","year":"2012","unstructured":"L\u00fcscher TF, Taddei S, Kaski J-C, Jukema JW, Kallend D, M\u00fcnzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33(7):857\u201365.","journal-title":"Eur Heart J"},{"issue":"22","key":"2317_CR37","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"2317_CR38","first-page":"372","volume":"8","author":"J-C Tardif","year":"2015","unstructured":"Tardif J-C, Rh\u00e9aume E, Lemieux Perreault L-P, Gr\u00e9goire JC, Feroz Zada Y, Asselin G, et al. Pharmacogenomic determinants of the cardiovascular effects of Dalcetrapib. Circulation: Cardiovascular Genetics. 2015;8(2):372\u201382.","journal-title":"Circulation: Cardiovascular Genetics"},{"issue":"3","key":"2317_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14779072.2020.1745633","volume":"18","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Bubb K. The mystery of evacetrapib - why are CETP inhibitors failing? Expert Rev Cardiovasc Ther. 2020;18(3):127\u201330.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"39","key":"2317_CR40","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1093\/eurheartj\/ehac374","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Pfeffer MA, Kouz S, Koenig W, Maggioni AP, McMurray JJ, et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J. 2022;43(39):3947\u201356.","journal-title":"Eur Heart J"},{"issue":"14","key":"2317_CR41","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJ. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919\u201331.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2317_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","volume":"243","author":"AJ Vallejo-Vaz","year":"2015","unstructured":"Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJP, Mata P, et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis. 2015;243(1):257\u20139.","journal-title":"Atherosclerosis"},{"key":"2317_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","volume":"277","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Collaboration EASFHS, Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiberger T, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS familial hypercholesterolaemia studies collaboration (FHSC). Atherosclerosis. 2018;277:234\u201355.","journal-title":"Atherosclerosis"},{"issue":"13","key":"2317_CR44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. HPS3\/TIMI55\u2013Reveal collaborative Group; effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327.","journal-title":"N Engl J Med"},{"key":"2317_CR45","unstructured":"Anonymous. 2017 [Available from: https:\/\/www.reuters.com\/article\/business\/healthcare-pharmaceuticals\/merck-says-will-not-seek-approval-of-cholesterol-treatment-idUSKBN1CG2VY"},{"issue":"24","key":"2317_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018136","volume":"9","author":"MP Metzinger","year":"2020","unstructured":"Metzinger MP, Saldanha S, Gulati J, Patel KV, El-Ghazali A, Deodhar S, et al. Effect of anacetrapib on cholesterol efflux capacity: a substudy of the DEFINE trial. J Am Heart Assoc. 2020;9(24):e018136.","journal-title":"J Am Heart Assoc"},{"key":"2317_CR47","doi-asserted-by":"publisher","unstructured":"Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better. Am J Prev Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100649.","DOI":"10.1016\/j.ajpc.2024.100649"},{"issue":"20","key":"2317_CR48","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"2317_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00671-y","volume":"18","author":"T Poliakova","year":"2023","unstructured":"Poliakova T, Wellington CLJM. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia. Mol Neurodegener. 2023;18(1):86.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2317_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13195-024-01594-6","volume":"16","author":"AF Schmidt","year":"2024","unstructured":"Schmidt AF, Davidson MH, Ditmarsch M, Kastelein JJ. Finan CJAsr, therapy. Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimer\u2019s Res. 2024;16(1):228.","journal-title":"Alzheimer\u2019s Res"},{"key":"2317_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1171937","volume":"14","author":"J Ph\u00e9nix","year":"2023","unstructured":"Ph\u00e9nix J, C\u00f4t\u00e9 J, Dieme D, Recinto SJ, Oestereich F, Efrem S, et al. CETP inhibitor evacetrapib enters mouse brain tissue. Front Pharmacol. 2023;14:1171937.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2317_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000943","volume":"8","author":"V Menon","year":"2020","unstructured":"Menon V, Kumar A, Patel DR, St John J, Riesmeyer J, Weerakkody G, et al. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Res Care. 2020;8(1):e000943.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2317_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2021.102282","volume":"168","author":"EI Bahbah","year":"2021","unstructured":"Bahbah EI, Shehata MSA, Alnahrawi SI, Sayed A, Menshawey A, Fisal A, et al. Safety and efficacy of evacetrapib in patients with inadequately-controlled hypercholesterolemia and high cardiovascular risk; a meta-analysis of randomized placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2021;168:102282.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"12","key":"2317_CR54","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","volume":"77","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein JJ. New and emerging therapies for reduction of LDL-cholesterol and Apolipoprotein B: JACC focus seminar 1\/4. J Am Coll Cardiol. 2021;77(12):1564\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2317_CR55","first-page":"148","volume":"9","author":"SS Martin","year":"2023","unstructured":"Martin SS, Ditmarsch M, Simmons M, Alp N, Turner T, Davidson MH, et al. Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J. 2023;9(2):148\u201355.","journal-title":"Eur Heart J"},{"issue":"2","key":"2317_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","volume":"26","author":"JJP Kastelein","year":"2024","unstructured":"Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M. Obicetrapib: reversing the tide of CETP inhibitor disappointments. Curr Atheroscler Rep. 2024;26(2):35\u201344.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"2317_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","volume":"26","author":"B Chang","year":"2024","unstructured":"Chang B, Laffin LJ, Sarraju A, Nissen SEJCAR. Obicetrapib\u2014the rebirth of CETP inhibitors? Curr Atheroscler Rep. 2024;26(10):603\u20138.","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"2317_CR58","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"2317_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503.","journal-title":"J Clin Lipidol"},{"key":"2317_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2024.09.013","volume":"278","author":"S Tsimikas","year":"2024","unstructured":"Tsimikas S, Yang X, Hsieh A, Ditmarsch M, Davidson M, Kastelein J. Obicetrapib demonstrates significant deductions of LP(A) on top of high-intensity statins. Am Heart J. 2024;278:3. https:\/\/doi.org\/10.1016\/j.ahj.2024.09.013.","journal-title":"Am Heart J"},{"issue":"10","key":"2317_CR61","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2174\/0929867324666170112111948","volume":"24","author":"N Katsiki","year":"2017","unstructured":"Katsiki N, Al-Rasadi K, Mikhailidis DP. Lipoprotein (a) and cardiovascular risk: the show must go on. Curr Med Chem. 2017;24(10):989\u20131006.","journal-title":"Curr Med Chem"},{"issue":"10","key":"2317_CR62","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2174\/092986732410170526175719","volume":"24","author":"GD Kolovou","year":"2017","unstructured":"Kolovou GD, Katsiki N, Mikhailidis DP, Editorial. Lipoprotein (a), more than just cholesterol? Curr Med Chem. 2017;24(10):952\u20136.","journal-title":"Curr Med Chem"},{"issue":"4","key":"2317_CR63","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/ph16040577","volume":"16","author":"N Katsiki","year":"2023","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I, Inclisiran. Low-Density lipoprotein cholesterol and lipoprotein. Pharmaceuticals (Basel). 2023;16(4):577.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"2317_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050753","volume":"18","author":"N Katsiki","year":"2025","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Lp(a)-lowering agents in development: a new era in tackling the burden of cardiovascular risk? Pharmaceuticals (Basel). 2025;18(5):753.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2317_CR65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","volume":"120","author":"F Gomez-Delgado","year":"2024","unstructured":"Gomez-Delgado F, Raya-Cruz M, Katsiki N, Delgado-Lista J, Perez-Martinez P. Residual cardiovascular risk: when should we treat it? Eur J Intern Med. 2024;120:17\u201324.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2317_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/0115701611267835231210054909","volume":"22","author":"D Mukherjee","year":"2024","unstructured":"Mukherjee D, Nissen SE. Lipoprotein (a) as a biomarker for cardiovascular diseases and potential new therapies to mitigate risk. Curr Vasc Pharmacol. 2024;22(3):171\u20139.","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"2317_CR67","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jacl.2016.06.006","volume":"10","author":"JC van Capelleveen","year":"2016","unstructured":"van Capelleveen JC, Kastelein JJ, Zwinderman AH, van Deventer SJ, Collins HL, Adelman SJ, et al. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. J Clin Lipidol. 2016;10(5):1137\u201344. e3.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"2317_CR68","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.5551\/jat.64828","volume":"31","author":"M Harada-Shiba","year":"2024","unstructured":"Harada-Shiba M, Davdison MH, Ditmarsch M, Hsieh A, Wuerdeman E, Kling D, et al. Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial. J Atheroscler Thromb. 2024;31(10):1386\u201397.","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"2317_CR69","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jacl.2022.05.059","volume":"16","author":"D Kling","year":"2022","unstructured":"Kling D. Obicetrapib lowers LDL-C in patients taking high intensity Statins-Results from the ROSE clinical trial. J Clin Lipidol. 2022;16(3):e73.","journal-title":"J Clin Lipidol"},{"issue":"9992","key":"2317_CR70","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. Cholesterol ester transfer protein Inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452\u201360.","journal-title":"Lancet"},{"issue":"2","key":"2317_CR71","doi-asserted-by":"publisher","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","volume":"309","author":"K Miyosawa","year":"2015","unstructured":"Miyosawa K, Watanabe Y, Murakami K, Murakami T, Shibata H, Iwashita M, et al. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. Am J physiology-endocrinology Metabolism. 2015;309(2):E177\u201390.","journal-title":"Am J physiology-endocrinology Metabolism"},{"issue":"10491","key":"2317_CR72","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","volume":"405","author":"A Sarraju","year":"2025","unstructured":"Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757\u201368.","journal-title":"Lancet"},{"issue":"1","key":"2317_CR73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJ, Ballantyne CM, Ray KK, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med. 2025;393(1):51\u201361.","journal-title":"N Engl J Med"},{"key":"2317_CR74","doi-asserted-by":"publisher","first-page":"106972","DOI":"10.1016\/j.phrs.2023.106972","volume":"197","author":"N Mehta","year":"2023","unstructured":"Mehta N, Dangas K, Ditmarsch M, Rensen PCN, Dicklin MR, Kastelein JJP. The evolving role of cholesteryl ester transfer protein Inhibition beyond cardiovascular disease. Pharmacol Res. 2023;197:106972.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2317_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00671-y","volume":"18","author":"T Poliakova","year":"2023","unstructured":"Poliakova T, Wellington CL. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia. Mol Neurodegener. 2023;18(1):86.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"2317_CR76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41574-021-00612-z","volume":"18","author":"N Katsiki","year":"2022","unstructured":"Katsiki N, Mikhailidis DP. Statins and diabetes mellitus progression: a fly in the ointment? Nat Rev Endocrinol. 2022;18(3):137\u20138.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2317_CR77","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.metabol.2014.11.001","volume":"64","author":"N Katsiki","year":"2015","unstructured":"Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism. 2015;64(4):471\u20135.","journal-title":"Metabolism"},{"issue":"18","key":"2317_CR78","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2174\/1381612822666160125114626","volume":"22","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Statins and type 2 diabetes mellitus: an update after 1 year. Curr Pharm Des. 2016;22(18):2723\u20135.","journal-title":"Curr Pharm Des"},{"key":"2317_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.atherosclerosis.2018.09.033","volume":"278","author":"PJ Barter","year":"2018","unstructured":"Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis. 2018;278:143\u20136.","journal-title":"Atherosclerosis"},{"key":"2317_CR80","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","volume":"44","author":"W Masson","year":"2018","unstructured":"Masson W, Lobo M, Siniawski D, Huer\u00edn M, Molinero G, Val\u00e9ro R, et al. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes Metab. 2018;44:508\u201313.","journal-title":"Diabetes Metab"},{"key":"2317_CR81","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2337\/dc19-2204","volume":"43","author":"GG Schwartz","year":"2020","unstructured":"Schwartz GG, Leiter LA, Ballantyne CM, Barter PJ, Black DM, Kallend D, et al. Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease. Diabetes Care. 2020;43:1077\u201384.","journal-title":"Diabetes Care"},{"issue":"3","key":"2317_CR82","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.jacl.2025.04.167","volume":"19","author":"K Kausik","year":"2025","unstructured":"Kausik K, Ray M, Szarek AM, Navar, Adam J, Nelson, Christie M, Ballantyne D, Kling M, Ditmarsch MH, Davidson JJP, Kastelein, Stephen J, Nicholls. Effect of obicetrapib on new onset diabetes in patients with elevated LDL-C receiving maximally tolerated Statin therapy: pooled analyses of the Broadway and Brooklyn trials. J Clin Lipidol. 2025;19(3):e116\u20137.","journal-title":"J Clin Lipidol"},{"key":"2317_CR83","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1161\/ATVBAHA.114.304131","volume":"34","author":"BJ Cochran","year":"2014","unstructured":"Cochran BJ, Bisoendial RJ, Hou L, Glaros EN, Rossy J, Thomas SR, et al. Apolipoprotein A-I increases insulin secretion and production from pancreatic \u03b2-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism. Arterioscler Thromb Vasc Biol. 2014;34:2261\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2317_CR84","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.108.843219","volume":"119","author":"BG Drew","year":"2009","unstructured":"Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, Courten B, de Forbes JM, Yap FY, Kaye DM, Hall G, van Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119:2103\u201311.","journal-title":"Circulation"},{"key":"2317_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056601","volume":"8","author":"AL Carey","year":"2013","unstructured":"Carey AL, Siebel AL, Reddy-Luthmoodoo M, Natoli AK, D\u2019Souza W, Meikle PJ, et al. Skeletal muscle insulin resistance associated with cholesterol-induced activation of macrophages is prevented by high density lipoprotein. PLoS ONE. 2013;8:e56601.","journal-title":"PLoS ONE"},{"issue":"3","key":"2317_CR86","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/biomedicines9030286","volume":"9","author":"GI Colombo","year":"2021","unstructured":"Colombo GI, Bianconi V, Bonomi A, Simonelli S, Amato M, Frigerio B, et al. The association between HDL-C and subclinical atherosclerosis depends on CETP plasma concentration: insights from the IMPROVE study. Biomedicines. 2021;9(3):286.","journal-title":"Biomedicines"},{"issue":"3","key":"2317_CR87","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bcp.12380","volume":"78","author":"J Ford","year":"2014","unstructured":"Ford J, Lawson M, Fowler D, Maruyama N, Mito S, Tomiyasu K, et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2014;78(3):498\u2013508.","journal-title":"Br J Clin Pharmacol"},{"issue":"9983","key":"2317_CR88","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","volume":"385","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385(9983):2153\u201361.","journal-title":"Lancet"},{"issue":"1","key":"2317_CR89","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jvs.2017.11.029","volume":"67","author":"L Bowman","year":"2018","unstructured":"Bowman L, Hopewell J, Chen F, Wallendszus K, Stevens W. Effects of anacetrapib in patients with atherosclerotic vascular disease. J Vasc Surg. 2018;67(1):356.","journal-title":"J Vasc Surg"},{"issue":"25","key":"2317_CR90","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","volume":"363","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM Jr, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"2317_CR91","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.amjcard.2017.03.255","volume":"120","author":"CM Ballantyne","year":"2017","unstructured":"Ballantyne CM, Shah S, Sapre A, Ashraf TB, Tobias SC, Sahin T, et al. A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. Am J Cardiol. 2017;120(4):569\u201376.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2317_CR92","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.21037\/jtd.2017.07.75","volume":"9","author":"TD Filippatos","year":"2017","unstructured":"Filippatos TD, Elisaf MS. Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy. J Thorac Dis. 2017;9(8):2308.","journal-title":"J Thorac Dis"},{"issue":"19","key":"2317_CR93","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.2011.1649","volume":"306","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang M-D, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099\u2013109.","journal-title":"JAMA"},{"key":"2317_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-025-00740-1","author":"JJP Kastelein","year":"2025","unstructured":"Kastelein JJP, Ditmarsch M, Hsieh A, Kling D, Walker A, Dicklin MR, et al. A drug-drug interaction study evaluating the pharmacokinetic consequences of obicetrapib therapy on Atorvastatin or Rosuvastatin levels in healthy volunteers. Am J Cardiovasc Drugs. 2025. https:\/\/doi.org\/10.1007\/s40256-025-00740-1.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"2317_CR95","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/jcph.6121","volume":"65","author":"J Zhang","year":"2024","unstructured":"Zhang J, Cao G, Huo Y, Guarneri LL, Ditmarsch M, Kastelein JJP, et al. A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose clinical trial to investigate the Pharmacokinetic, Pharmacodynamic, and safety profiles of obicetrapib in healthy participants in China. J Clin Pharmacol. 2024;65(1):96\u2013107.","journal-title":"J Clin Pharmacol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02317-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:01:48Z","timestamp":1767686508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02317-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02317-5","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"10"}}